Highlights • Switched memory B-cells guide rituximab retreatment intervals in NMOSD • Individualised rituximab dosing maintains efficacy with less drug exposure in NMOSD • Individualised rituximab dosing is cost-effective in NMOSD • Rituximab is likely to remain a mainstay of treatment for NMOSD Abstract Background B-cell depleting treatments are widely used to modify the course of neuromyelitis optica spectrum disorder (NMOSD).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile